Telesis Bio Operating Income 2021-2024 | TBIO

Telesis Bio operating income from 2021 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Telesis Bio Operating Income 2021-2024 | TBIO

Telesis Bio operating income from 2021 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$142.2B
Bristol Myers Squibb (BMY)$117.1B
Gilead Sciences (GILD)$117.1B
Vertex Pharmaceuticals (VRTX)$105.1B
CSL (CSLLY)$85.9B
Regeneron Pharmaceuticals (REGN)$78.5B
GSK (GSK)$70.5B
Argenex SE (ARGX)$38B
Alnylam Pharmaceuticals (ALNY)$31.4B
BioNTech SE (BNTX)$27.4B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$17.7B
Moderna (MRNA)$15.5B
Genmab (GMAB)$13.5B
Incyte (INCY)$13.5B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.6B
Exact Sciences (EXAS)$10.8B
Vaxcyte (PCVX)$10.7B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B